Compare SAMG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | ABOS |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | 164 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 113.9M |
| IPO Year | 2013 | 2021 |
| Metric | SAMG | ABOS |
|---|---|---|
| Price | $14.47 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 31.8K | ★ 172.5K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $125,322,000.00 | N/A |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $13.23 | $0.86 |
| 52 Week High | $19.20 | $2.46 |
| Indicator | SAMG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 49.78 |
| Support Level | $13.32 | $1.51 |
| Resistance Level | $13.79 | $2.03 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 100.00 | 63.89 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.